X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

PhRMA comments to Congress on Cures 2.0 call to action

By Anne McDonald Pritchett, PhD  |    December 18, 2019
As new therapies continue to revolutionize the treatment of many diseases, it is positive news that policymakers in Washington are discussing ways to ensure patient access to new treatments and...   Read More

What you need to know about H.R. 3

By Tom Wilbur  |    December 12, 2019
Speaker of the House Nancy Pelosi’s drug pricing proposal, H.R. 3, which is being voted on in the U.S. House of Representatives today, is unprecedented in size and scope. It dramatically expands...   Read More

R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures

By Andrew Powaleny  |    December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...   Read More

New NHE data: Medicine prices declined, and hospitals were biggest driver of health care spending in 2018

By Holly Campbell  |    December 6, 2019
According to new data from the National Health Expenditures (NHE), retail medicine prices declined by 1% and retail medicine spending grew just 2.5% in 2018. To put that in context, hospital...   Read More

New poll: 76% of voters concerned Speaker Pelosi’s plan would result in fewer new medicines

By Nicole Longo  |    December 5, 2019
The House of Representatives has spent much of this fall focused on Speaker Pelosi’s drug pricing bill, H.R.3, but a recent survey of nearly 2,000 registered voters confirms that H.R.3 is not the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates